EGFR and non-small cell lung carcinoma: With durvalumab use as an adjuvant therapy following concurrent chemoradiotherapy (CCRT) in stage III NSCLC (PACIFIC trial), hazard ration (HR) for PFS for the whole study population was 0.55 (95% CI 0.45–0.68) in favour of durvalumab whereas, for EGFR-mutation positive patients, HR was not significant at 0.76 (95% CI 0.35–1.64) [23].